CLAIMS

1. A liquid preparation comprising a camptothecin derivative which is prepared by binding a compound of the formula [I]:



[I]

wherein R^1 is a substituted or unsubstituted lower alkyl group, X^1 is a group of the formula: $-NHR^2$ (R^2 is a hydrogen atom or a lower alkyl group) or a hydroxy group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom,
and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof, which is adjusted to pH 5-8.

2. The liquid preparation according to claim 1 wherein one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogen phosphate are used as the buffer.

3. The liquid preparation according to claim 2 wherein ionic strength of the buffer is 0.2 or less than 0.2.

4. The liquid preparation according to any one of claims 1

to 3 wherein the pH is adjusted to 5 to 7.5.

5. The liquid preparation according to any one of claims 1 to 3 wherein the pH is adjusted to 5 to 7.

6. The liquid preparation according to any of claims 1 to 3 wherein the pH is adjusted to 6 to 7.

7. The liquid preparation according to any one of claims 1 to 6 wherein the amount of the camptothecin derivative or its pharmaceutically acceptable salt is 1% to 20%.

8. The liquid preparation according to any one of claims 1 to 7 wherein one ore more ingredients selected from a stabilizer and a filler are further contained.

9. The liquid preparation according to any one of claims 1 to 8 wherein one ore more stabilizers selected from an alkali metal carbonate and alkali metal hydrogen carbonate, and one ore more fillers selected from lactose, sucrose, mannitol, dextran, maltose and trehalose are further contained.

10. The liquid preparation according to any one of claims 1 to 9 wherein one or more salts selected from an alkali metal chloride, an alkaline earth metal chloride and an alkali metal sulphate are further contained.

11. The liquid preparation according to claim 1 wherein R^1 is an unsubstituted C_{1-6} alkyl group, X^1 is an amino group and Alk is a straight chain C_{1-6} alkylene group not interrupted by an oxygen atom, a polysaccharide is a

carboxymethylated dextran or pullulan, and a peptide is a peptide consisting of 2 - 5 amino acids.

12. The liquid preparation according to claim 11 wherein R^1 is ethyl group, a group of the formula: X^1-Alk-O- is 3-aminopropyloxy group, and the camptothecin compound [I] is bound at position 10 of a camptothecin nucleus, the polysaccharide is dextran in which a carboxyl group is introduced, the peptide is glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycyl-glycine, L- or D-phenylalanyl-glycine, and L- or D-leucyl-glycine.

13. The liquid preparation according to claim 12 wherein the peptide is glycyl-glycyl-glycine.

14. A lyophilized drug composition prepared by lyophilizing the liquid preparation according to any one of claims 1 to 13.

15. A liquid composition for injection wherein the composition according to claim 14 is dissolved in an aqueous medium.